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Objective: To determine whether adding dehydroepiandrosterone to combined oral contraceptives (COCs) maintains physiological levels of
free testosterone.
Study design: A randomized, double-blind, placebo-controlled, two-way crossover study conducted in 81 healthy women (age range: 20–35
years; Body mass index (BMI) range: 18–35 kg/m2) using oral contraceptives. Androgens, sex hormone-binding globulin (SHBG), estradiol
(E2) and estrone (E1) were measured, and free testosterone and the free testosterone index were calculated. Subjects discontinued oral
contraceptive use for at least one menstrual cycle before being randomized to receive five cycles of ethinyl estradiol (EE) combined with
either levonorgestrel (EE/LNG group) or drospirenone (EE/DRSP group) together with either dehydroepiandrosterone (DHEA) (50 mg/day
orally) or placebo. Subsequently, all subjects crossed over to the other treatment arm for an additional five cycles.
Results: Both COCs decreased the levels of all androgens measured. Significant decreases (pb.05) were found with EE/LNG and EE/DRSP for
total testosterone (54.5% and 11.3%, respectively) and for free testosterone (66.8% and 75.6%, respectively). Adding DHEA to the COCs
significantly increased all androgens compared to placebo. Moreover, including DHEA restored free testosterone levels to baseline values in both
COC groups and total testosterone levels to baseline in the EE/LNG group and above baseline in the EE/DRSP group. SHBG concentrations were
significantly higher with EE/DRSP compared to EE/LNG (pb.0001). The addition of DHEA did not affect the levels of SHBG.
Conclusions: Taking COCs reduces total and free testosterone levels and increases SHBG concentrations. By coadministration with DHEA,
physiological levels of total and free testosterone are restored while using EE/LNG. With EE/DRSP, only the free testosterone level is
normalized by DHEA coadministration.
Implications: A daily oral dose of 50-mg DHEA maintains physiological free and total testosterone levels in women who are using an EE/
LNG-containing COC.
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In women, testosterone (T) is believed to play an
important role in sexual function; specifically, T is
associated with sexual desire, the ability to achieve orgasm,
and the frequency of sexual intercourse [1–3]. Thus, T
therapy may represent an effective strategy for treating
decreased sexual desire related to low free T levels that is
common among postmenopausal women, in women ap-
proaching their late reproductive years and in women with
ovarian and/or pituitary dysfunction [4–12].
The majority of circulating T is either tightly bound to sex
hormone-binding globulin (SHBG) or weakly bound to
albumin; only 0.5–3.0% circulates as free T [13,14].
Because T binds to albumin with relatively low affinity,
the pools of free and albumin-bound T are defined together
as bioavailable T [13,14]; this is also represented using the
free T index (FTI), a calculated value of bioavailable T.
Combined oral contraceptives (COCs) significantly lower
the levels of androgens, including free T, in women [14].
With respect to T, this reduction is caused by several
processes, including the suppression of ovarian and adrenal
androgen production, the suppression of peripheral T
synthesis and the stimulation of SHBG production in the
liver; the last of these effects is due to the estrogenic
component of COCs, ethinyl estradiol (EE), which stimu-
lates hepatic SHBG production.
Although studies of the effects of COCs on mood and
sexual function have yielded conflicting results [15–21], the
reduction in free T levels is a plausible mechanism by which
COCs can negatively affect sexual function, at least in some
women [2,22–24].
Based on these findings, we hypothesized that the
negative effects of COCs on sexual function may be
improved by maintaining physiological levels of androgens,
particularly free T, in these women. Physiological levels of
androgens may be achieved by adding dehydroepiandros-
terone (DHEA) — a naturally occurring androgenic
hormone produced by the adrenal gland — to COCs.
Because oral DHEA is partially metabolized by the liver into
T [25–28], it could in principle be incorporated as a prodrug
into a COC pill, thereby maintaining T levels in women who
use these COCs. Previous studies found that adding a daily
dose of 50-mg DHEA to a drospirenone (DRSP)-containing
COC significantly increased total T levels; however, free T
was restored to only 47% of normal, presumably due to the
EE-induced increase in T-binding SHBG [29].
Although most COCs contain EE, the progestin compo-
nent in COCs varies. Different progestins have different
intrinsic antiestrogenic and androgenic potencies. For
example, levonorgestrel (LNG) has antiestrogenic effects
on SHBG levels, thereby counteracting the EE-induced
increase in SHBG; in contrast, DRSP does not interfere
with the effect of EE on SHBG [5]. In addition, LNG has
intrinsic androgenic effects, whereas DRSP exhibits anti-
androgenicity [14]. Thus, DRSP-containing COCs causes amore robust reduction of androgenicity than LNG-
containing COCs.
Here, we studied the endocrine effects of including
DHEA in COCs containing 30-mcg EE in combination with
either 150-mcg LNG or 3-mg DRSP. Specifically, we
measured androgen levels and androgen-related endrocrine
parameters (including T, SHBG and free T) and clinical
parameters. In this paper, we present the endocrine effects; in
our companion paper, we present the clinical effects,
including sexual function, dermatological findings and
safety (e.g., effects on lipids and skin) [30].2. Materials and methods
2.1. Study population
The following criteria were used to determine eligibility
for inclusion in the study: prior to screening, subjects had to
have used a contraceptive pill for at least 3 months and had to
have been in a stable, satisfactory, heterosexual relationship
for at least 3 months; 20–35 years of age; body mass index
(BMI) of 18–35 kg/m2; at least one regular menstrual cycle
(lasting 24–35 days) prior to the last start of COC use; total T
level b5 nmol/L; and willing to interrupt COC use for a
period of at least 4 weeks (one menstrual cycle).
The study was approved by the medical ethics committee
of the Academic Medical Center (AMC) (Amsterdam, the
Netherlands) and was conducted in accordance with the
Declaration of Helsinki and the International Conference on
Harmonization/Good Clinical Practice guidelines. All par-
ticipants provided written informed consent. The study was
registered at the ISRCTN registry (no. ISRCTN03247616).
2.2. Study design and procedures
This randomized, double-blind, placebo-controlled,
two-way crossover study was conducted at the AMC
(Amsterdam, the Netherlands). The primary objective, the
results of which are reported in our companion paper [30],
was to determine and compare the effects of DHEA versus
placebo on sexual function in subjects using a COC
containing 30-mcg EE with either 3-mg DRSP (EE/DRSP
group) or 150-mcg LNG (EE/LNG group). The secondary
objective, which we report here, was to evaluate the effect of
DHEA versus placebo on endrocrine parameters in these two
COC groups.
In accordance with the study protocol, each subject
discontinued using their contraceptive pill for one regular
cycle (the baseline cycle period; Fig. 1). After this cycle, the
subjects were assigned randomly to either the EE/DRSP or
EE/LNG group. The subjects then took their assigned COC
together with either DHEA or placebo for five 28-day cycles
(each cycle consisted of 21 days on the COC followed by 7
days off the COC; DHEA or placebo was taken throughout
the cycle). After the first five cycles (Treatment Period 1),
the subjects then crossed over (i.e., subjects who took DHEA
Fig. 1. Study design and subject disposition.
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versa) for an additional five cycles (Treatment Period 2). The
study design is depicted in Fig. 1.
2.3. Endocrine parameters
Plasma samples for measuring endocrine parameters were
taken at screening (during the subject's prior COC use),
between days 14 and 17 during the pretreatment cycle
(baseline) and between days 14 and 17 in the fifth cycle in
each treatment period. Plasma samples were analyzed at the
AMC laboratory using radioimmunoassay to measure total
extracted T, SHBG, DHEA, DHEA-sulfate (DHEA-S),
Δ4-androstenedione (AD), estradiol (E2), and E1; albumin
was measured using a bromocresol assay. The lower limits of
quantification were as follows: total T, 0.3 nmol/L; SHBG, 5
nmol/L; DHEA, 1.5 nmol/L; DHEA-S, 0.1 μmol/L, AD, 0.4
nmol/L; and E2, 40 pmol/L. Because a method for directly
measuring free T was not available at our laboratory when
the study was performed, free T was calculated based on total
T, SHBG and albumin concentration [31,32]. In addition,
FTI was calculated using the following formula: FTI=
100×[T]/[SHBG], where T is total T [32].
2.4. Study medication
DHEAwas manufactured by Akzo Laboratories (Diosynth
B.V., Oss, the Netherlands) in accordance with Good
Manufacturing Practices. The DHEA and placebo tabletswere manufactured by Unither Pharmaceuticals (Le Haillan,
France) and were identical in appearance. Blinded study
medication was packed per subject number according to
a computer-generated randomization list that was only known
to an independent biostatistician. The subjects received either a
COC containing 30-mcg EE+3-mg DRSP (Yasmin; Bayer
Healthcare, Berlin, Germany) or a COC containing 30-mcg
EE+150-mcg LNG (Microgynon; Bayer Healthcare).
2.5. Statistical analysis and sample size calculation
Based on the primary objective of achieving awithin-subject
effect size of 0.5 with respect to sexual function, with a
significance level of 5% and a power of 80%, a minimum of 36
subjects was required [33]. Thus, because two different COCs
(EE/DRSP and EE/LNG) were used in this study, a minimum
of 72 evaluable subjects in total was required.
The data were analyzed based on an intention-to-treat
approach. Unless indicated otherwise, all summary results
are expressed as the mean±SD. A log-transform was used to
normalize skewed distributions, and all subsequent calcula-
tions were performed on the log-transformed data. When
variables could not be normalized, nonparametric tests were
used. The one-way analysis of variance or the Kruskal–
Wallis test was used to compare values in the four
randomized groups, whereas the chi-square test or Fisher's
Exact Test was used for categorical variables. Crossover data
recorded at the end of Treatment Periods 1 and 2 were
analyzed as described by Altman [34]. Specifically, for each
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effect were tested using the unpaired Student t test or the
Kruskal–Wallis test; in the absence of such effects, the
treatment effect was tested using a paired Student t test or the
Wilcoxon signed-rank test on the combined sequence data.
The COC effect was assessed by comparing the overall
levels in each COC group using an unpaired Student t test or
the Kruskal–Wallis test. The same analysis was repeated on
data that were adjusted for baseline values.
The paired Student t test or Wilcoxon signed-rank test
was used to analyze the within-subject changes between the
following measurement pairs: screening versus baseline;
Treatment Period 1 versus baseline; and Treatment Period 2
versus baseline. Differences were considered to be signifi-
cant at pb.05. A Bonferroni correction was applied to the
crossover tests (pb.01). All analyses were performed using
SAS (Version 9.3 for Windows, SAS Institute, Cary, NC,
USA) and S-PLUS (Version 8.1 for Windows, Tibco
Software, Palo Alto, CA, USA) statistical packages.Table 1
Baseline characteristics of the study population (n=74)
Parameter EE/DRSP
n=37
DHEA-P1
n=18
P-DHEA2
n=19
Age, years 25.0±3.9 24.5±3.0
BMI, kg/m2 23.3±2.7 22.2±2.6
Ethnic origin, n (%)
Caucasian 14 (77.8) 19 (100.0
Asian 1 (5.6) 0 (0.0)
Other 3 (16.7) 0 (0.0)
OC type used at screening, n (%)
LNG+EE 11 (61.1) 12 (63.2)
CYP+EE 2 (11.1) 2 (10.5)
DRSP + EE 2 (11.1) 1 (5.3)
DSG+EE 1 (5.6) 2 (10.5)
GSD+EE 1 (5.6) 1 (5.6)
LYN+EE 1(5.6) 0 (0.0)
DSG 0 (0.0) 0 (0.0)
NOR + EE 0 (0.0) 1 (5.3)
Endocrine parameters
Total T (nmol/L) 1.4±0.7 1.1±0.5
SHBG (nmol/L) 87.0±54.3 85.4±31.2
Albumin (g/L) 44.3±3.2 43.0±4.4
Free T (pmol/L) 21.8±11.9 12.9±5.9
FTI 2.1±1.1 1.8±2.3
DHEA (nmol/L) 34.8±12.9 40.3±13.6
DHEA-S (μmol/L) 5.0±2.8 5.8±2.3
AD (nmol/L) 7.4±3.0 7.3±2.1
E2 (pmol/L) 212±254 229±261
E1 (nmol/L) 0.4±0.2 0.5±0.2
Data are expressed as mean±standard deviation or n (%).
CYP, cyproterone; DSG, desogestrel; E2, 17ß-estradiol; GSD, gestodene; n, num
1 DHEA-P, DHEA in Treatment Period 1 and placebo in Treatment Period 2
2 P-DHEA, placebo in Treatment Period 1 and DHEA in Treatment Period 23. Results
3.1. Study population
A total of 92 women who were using a COC were
screened; 82 of these women who met all of the study criteria
were randomized, and 81 entered the study. Seven women
withdrew from the study due to withdrawal of consent with
no further explanation (n=2), high T levels (n=1), severe
acne (n=1), headache (n=1), termination of her relationship
with partner (n=1) or personal reasons (n=1). Thus, a total of
74 women completed the study (Fig. 1).
The baseline characteristics of the study population
are summarized in Table 1. The majority of the subjects
(91%) were of Caucasian descent. The EE/DRSP and EE/
LNG groups were similar with respect to age, BMI,
ethnicity, type of COC used prior to the study and endocrine
parameters (Table 1). The majority (73%) of subjects had
been taking an LNG-containing COC at the time of
screening (Table 1).EE/LNG
n=37
p-value
(EE/DRSP
vs. EE/LNG)
DHEA-P1
n=19
P-DHEA2
n=18
24.2±4.0 22.4±3.2 0.16
22.8±3.6 23.3±2.7 0.63
0.17
) 17 (89.5) 17 (94.4)
0 (0.0) 0 (0.0)
2 (10.5) 1 (5.6)
0.081
14 (73.7) 17 (94.4)
2 (10.5) 1 (5.6)
2 (10.5) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
0 (0.0) 0 (0.0)
1 (5.3) 0 (0.0)
0 (0.0) 0 (0.0)
1.4±0.6 1.4±0.7 0.24
84.0±55.5 72.2±36.1 0.65
44.8±2.9 45.3±2.7 0.62
21.9±13.5 25.0±22.4 0.19
2.4±1.8 2.5±1.9 0.32
43.6±18.3 41.0±17.3 0.52
5.8±2.9 5.6±1.9 0.53
8.3±2.9 8.2±3.4 0.63
182±187 306±252 0.28
0.5±0.2 0.5±0.3 0.38
ber of subjects; NOR, norethisterone; OC, oral contraceptive; P, placebo.
.
.
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Nearly all endocrine parameters increased significantly at
the end of the baseline (COC-free cycle) period compared to
their respective values at screening. In contrast, SHBG levels
decreased significantly and albumin concentration was
unchanged (data not shown).
An analysis of the crossover data for all parameters
revealed no significant period and/or treatment×period
interaction effect; therefore, the data in the two treatment
periods were combined. Table 2 summarizes the change
relative to baseline after five cycles with 50 mg/day DHEA
or placebo. After five cycles, all parameters (except SHBG,
albumin and E2) differed significantly between DHEA and
placebo in both COC groups (Table 2).
3.2.1. Total T
Significantly higher total T levels were measured in the
DHEA treatment period compared with their respective
placebo treatment (Fig. 2A). In the placebo treatment period,
total T decreased significantly compared to baseline (pb.05
and pb.0001 in the EE/DRSP and EE/LNG groups,
respectively) (Table 2; Fig. 2A). In contrast, in the DHEA
treatment period, total T levels increased significantlyTable 2
Endocrine parameters at baseline and after five cycles of EE/DRSP or EE/LNG w
Parameter COC group
(n=34–37)
Baseline Placebo
Absolute change
relative to baseline
Mean pe
relative
Total T (nmol/L) EE/DRSP 1.24±0.61 −0.14±1.12⁎ −
EE/LNG 1.43±0.63 −0.78±0.59⁎ −
SHBG (nmol/L) EE/DRSP 86.2±43.4 164±87.2⁎ +1
EE/LNG 78.3±46.8 18.1±47.6⁎ +
Albumin (g/L) EE/DRSP 43.6±3.86 −0.69±4.17 −
EE/LNG 45.0±2.77 −1.55±4.89 −
Free T (pmol/L) EE/DRSP 17.2±10.2 −13.0±11.8⁎ −
EE/LNG 23.2±17.7 −15.5±16.8⁎ −
FTI EE/DRSP 1.91±1.83 −1.43±1.89⁎ −
EE/LNG 2.46±1.82 −1.71±1.70⁎ −
DHEA (nmol/L) EE/DRSP 37.6±13.4 −8.19±22.9⁎ −
EE/LNG 42.4±17.6 −13.7±17.0⁎ −
DHEA-S (μmol/L) EE/DRSP 5.40±2.56 −1.19±3.15⁎ −
EE/LNG 5.72±2.45 −1.12±2.94⁎ −
AD (nmol/L) EE/DRSP 7.34±2.57 −1.92±4.07⁎ −
EE/LNG 8.26±3.07 −3.27±2.76⁎ −
E2 (pmol/L)3 EE/DRSP 221±254 −177±258⁎ −
EE/LNG 242±227 −202±227⁎ −
E1 (nmol/L) EE/DRSP 0.48±0.23 −0.18±0.27⁎ −
EE/LNG 0.48±0.23 −0.12±0.25⁎ −
Data expressed as mean±standard deviation.
n, number of subjects; NA, not applicable.
1 Analysis of the crossover data did not reveal any significant period and/or
periods were combined.
2 Comparison of absolute value at end of treatment.
3 Measured E2 values were below the detection threshold in 89–100% of sam
limit of detection (40 pmol/L).
⁎ pb.05 versus baseline.compared to baseline in the EE/DRSP group (pb.0001) but
not in the EE/LNG group (p=.15) (Table 2; Fig. 2A).
3.2.2. SHBG
The SHBG levels were similar between the DHEA and
placebo treatment periods in both the EE/DRSP (p=.081) and
EE/LNG (p=.40) groups (Table 2; Fig. 2B). However,
compared to baseline, SHBG levels increased in both the EE/
DRSP and EE/LNG groups, regardless of whether the
subjects received DHEA or placebo (Table 2; Fig. 2B). The
SHBG levels were significantly higher in the EE/DRSP
compared to the EE/LNG group (pb.0001; Table 2).
3.2.3. Free T
Our analysis revealed significant differences in free T
levels between the DHEA and placebo treatment periods in
both the EE/DRSP and EE/LNG groups (pb.0001 for each
group) (Table 2 and Fig. 2C). In the placebo treatment
period, free T decreased significantly compared to baseline
in both the EE/DRSP and EE/LNG groups (pb.0001). In the
DHEA treatment period, free T levels were similar to
baseline values in both the EE/DRSP and EE/LNG groups.
However, free T levels were significantly higher in the EE/
LNG+DHEA group than in the EE/DRSP + DHEA groupith 50 mg/day DHEA or placebo1
DHEA p-value
(DHEA vs.
placebo)2
rcent change
to baseline
Absolute change
relative to baseline
Mean percent change
relative to baseline
11.3% 1.78±1.56⁎ +143.5% b0.0001
54.5% 0.25±0.85 +17.5% b0.0001
90.3% 145±75.8⁎ +168.2% 0.081
23.1% 14.9±49.0⁎ +19.0% 0.40
1.6% 0.12±4.08 +0.3% 0.081
3.4% −1.12±3.57 −2.5% 0.32
75.6% −3.33±10.8 −19.4% b0.0001
66.8% −3.76±19.5 −16.2% b0.0001
74.9% −0.53±1.87 −27.7% b0.0001
69.5% −0.51±1.86 −20.7% b0.0001
21.8% 25.0±37.2⁎ +66.5% b0.0001
32.3% 9.10±30.3 +21.5% b0.0001
22.0% 6.62±6.44⁎ +122.6% b0.0001
19.6% 6.25±7.86⁎ +109.3% b0.0001
26.2% 13.4±13.09⁎ +182.6% b0.0001
39.6% 4.37±11.6⁎ +52.9% b0.0001
80.1% −155±304⁎ −70.1% NA
83.5% −203±228⁎ −83.9% NA
37.5% 0.18±0.34⁎ +37.5% b0.0001
25.0% 0.20±0.34⁎ +41.7% b0.0001
treatment×period interaction effect, therefore, the data in the two treatment
ples obtained during the treatment period; these values were set to the lower
A) Total testosterone
B) Sex hormone-binding globulin
C) Free testosterone
EE/DRSP (n=34-37) EE/LNG (n=35-36)
Fig. 2. The absolute values of endocrine parameters (mean±standard
deviation) measured at baseline and after five cycles of EE/DRSP or EE/
LNG with 50-mg/day DHEA or placebo.
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when we calculated FTI rather than free T (see Table 2);
therefore, FTI levels are not discussed further.
3.2.4. DHEA, DHEA-S and AD
Compared to the placebo treatment period, DHEA,
DHEA-S and AD were all significantly increased in the
DHEA treatment period in both the EE/DRSP and EE/LNG
groups (pb.0001; Table 2). In the placebo treatment period,
the DHEA, DHEA-S and AD levels were decreased
significantly compared to baseline levels (pb.0001). In the
DHEA treatment period, all three androgens were increased
significantly compared to baseline in the EE/DRSP group
(pb.01); in the EE/LNG group, DHEA-S and AD levels were
increased significantly compared to baseline (pb.01),
whereas DHEA levels were unchanged. The DHEA and
DHEA-S levels were similar between the EE/DRSP and EE/
LNG groups, where the AD levels were significantly higher
in the EE/DRSP group (pb.01; Table 2).
3.2.5. E1 and E2
E1 levels were significantly increased in theDHEA treatment
period in both COC groups compared to placebo (pb.0001;
Table 2). In the placebo treatment period, both E1 and E2 were
decreased significantly compared to baseline in both COC
groups (pb.001). In the DHEA treatment period, E1 levels
increased compared to baseline in both COC groups (pb.01)
(Table 2). Compared to their respective baseline levels, E2 levels
were significantly decreased in both the EE/DRSP + DHEA
group (pb.005) and the EE/LNG+DHEA group (pb.0001).4. Discussion
Based on observations in the current study, we conclude
that adding 50 mg daily of DHEA to a COC containing
30-mcg EE along with either 3-mg DRSP or 150-mcg LNG
maintained physiological levels of free T in healthy women,
thereby preventing the significant reduction in free T levels
associated with the use of COCs. Importantly, in the women
receiving EE/DRSP, free T levels were restored to baseline,
but the inclusion of DHEA significantly increased total T
levels relative to baseline.
These results differ from our previous study using the
same DRSP-containing COC, in which free T levels were
restored to only 47% of baseline, and total T levels returned
to— but did not exceed— baseline levels [21]. Changes in
the levels of SHBG (which binds tightly to circulating T)
cannot explain this difference in results, as both studies
found that SHBG levels increased to a similar extent in the
COC-only groups, and the addition of DHEA did not affect
the levels of SHBG. On the other hand, the difference in
results with respect to T levels between these two studies
may be explained— at least in part— by the use of different
T assays, which are affected differently by high levels of
SHBG [35]; additional studies are needed to address this
issue. Ideally, free T concentration should not be calculated
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phy assays or equilibrium dialysis [8,36].
Androgens— particularly T— have become increasingly
appreciated as important hormones in both postmenopausal
and premenopausal women [4,9–12,37,38]. The crossover
design of our study allowed us to measure the effect of COC
use on androgen levels during five cycles and then compare
these results with the effect of COC combined with DHEA in
the same group of patients. In the placebo treatment period
(i.e., with the COC alone), all ovarian, adrenal and precursor
androgens measured were decreased significantly, which is
consistent with previous reports [14]. The addition of DHEA
for five cycles significantly increased the levels of both total T
and free T, E1 and the precursor androgens DHEA, DHEA-S
and AD. The increases in precursor androgen levels relative to
baseline are not considered to be clinically relevant, as these
prohormones are biologically inactive in the circulation [39]
and are relatively safe at the levels measured in our subjects.
The increase in E1 levels was relatively small (an increase of
approximately 40% above baseline) and is also not considered
to be a safety concern, particularly in light of the huge increase
in E1 associated with the new COCs that contain E2 [40–42].
Because COCs inhibit follicular development, in the
placebo treatment periods, E2 levels decreased significantly
relative to baseline in both COC groups. DHEA is
metabolized by the liver to produce both T and E2 [43];
however, it is important to note that E2 levels were not
increased during the DHEA treatment period in either COC
group. This finding suggests that a daily dose of 50-mg
DHEA is sufficient to maintain physiological levels of T but
does not affect E2 levels.
In conclusion, we confirm that the COCs EE/DRSP and
EE/LNG have strong suppressive effects on androgen levels.
Moreover, adding a daily dose of 50-mg DHEA to the COC
can maintain androgen levels in women using an
LNG-containing COC. In addition to the improved endocrine
outcome reported here, we report in our companion paper that
adding DHEA also improves the clinical outcome, particularly
with respect to some aspects of sexual function [30].Acknowledgments
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